Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics insider equity activity mixes sales and new awards. Officer Patrick Burnett sold 6,106 and 181 shares of common stock on March 2, 2026 at weighted average prices of $25.1604 and $25.9140. A footnote explains these sales were made to cover tax withholding obligations from vesting restricted stock units, rather than discretionary open‑market selling.
Burnett also received equity compensation on February 27, 2026, including a stock option grant for 77,000 shares and a 30,000‑share restricted stock unit award, both with no cash exercise or purchase price at grant. Another entry reflects 16,750 RSUs tied to an earlier performance grant whose milestone was certified on August 18, 2022. A separate footnote notes a prior reporting error that understated his beneficial ownership by 18 to 36 shares, now corrected.
Masaru Matsuda reported Rule 144 sale notices for Arcutis Biotherapeutics common stock. The filing lists sales of 40,638, 3,325 and 1,675 shares in the past three months, and separately lists restricted stock vesting of 6,746, 3,325 and 1,987 shares on the dates shown.
The broker listed is Merrill Lynch and the security trades on NASDAQ. The filing records transaction dates including 02/02/2026, 02/27/2026 and 12/01/2025.
Arcutis Biotherapeutics reports a proposed sale of common stock. The filing lists 3,687 shares of common stock described under "Securities To Be Sold" with an effective date of 03/01/2026. The excerpt also shows a prior sale by Todd Edwards of 2,052 common shares on 02/02/2026.
Arcutis Biotherapeutics submitted a notice to sell 37,349 common shares under a Rule 144-type transaction tied to restricted stock vesting on 03/01/2026.
The filing identifies Todd F. Watanabe as a related address and reports 19,833 common shares sold during the prior three months (sale date shown 02/02/2026).
Arcutis Biotherapeutics filed a Form 144 to sell 2,853 shares of common stock. The filing lists the securities to be sold in connection with restricted stock vesting on 03/01/2026. The filing also shows 1,320 shares sold during the prior three months on 02/02/2026.
Arcutis Biotherapeutics proposes the sale of 6,287 common shares following restricted stock vesting on 03/01/2026. The filing lists recent open‑market sales by reporting person Patrick Burnett, including 11,500 shares on 12/15/2025 and 9,794 shares on 02/04/2026.
Arcutis Biotherapeutics filed a Form 144 notice reporting the intended sale of 39,272 common shares for $997,194.62, dated 03/02/2026. The filing also lists stock option exercises of 27,052 (06/14/2024) and 12,220 (05/31/2023).
Arcutis Biotherapeutics, Inc. reporting a Form 144 sale notification for 10,000 common shares to be sold on 03/02/2026 on NASDAQ. The filing notes prior sales by Howard Welgus of 10,000 shares on 01/02/2026 for $289,606.03 and 10,000 shares on 02/02/2026 for $250,482.69.
Arcutis Biotherapeutics filed a shelf registration statement to register multiple securities for potential future offerings. The prospectus covers common stock, preferred stock, debt securities, warrants, purchase contracts and units and permits selling securityholders to resell shares. The company states it will not receive proceeds from selling securityholders’ resales.
Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology-focused biopharmaceutical company centered on its topical PDE4 franchise ZORYVE and its biologic candidate ARQ-234. The company now markets four ZORYVE formulations across plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp/body psoriasis in the United States and Canada, with multiple pediatric label expansions and additional sNDAs planned.
Arcutis estimates an actively prescription-treated U.S. market of about 17 million topical patients across its core diseases and aims to position ZORYVE as a chronic, non-steroidal alternative to topical steroids, expanding from dermatology into primary care and pediatrics. Its strategy also includes life-cycle indication expansion (such as hidradenitis suppurativa and vitiligo), international licensing deals in Japan and Asia, and advancement of ARQ-234, a CD200R agonist being prepared for Phase 1 in atopic dermatitis with broader inflammatory potential.